Wall Street Wizardry
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Wall Street Wizardry

Investing

Don Durrett: Gold, Silver Price Targets and 15 “Must-Own” Silver Stocks

by admin February 8, 2025
February 8, 2025
Don Durrett: Gold, Silver Price Targets and 15 “Must-Own” Silver Stocks

However, there could be a pullback before that happens. Although gold and silver prices are thriving now, Durrett believes a ‘rug pull’ could take gold down to the US$2,350 to US$2,400 per ounce level.

After that happens, gold will be ‘off to the races,’ with silver following. He anticipates gold rising to the US$3,200 to US$3,400 range, while silver could make it anywhere between US$45 and US$65 per ounce.

In closing, Durrett listed his 15 ‘must-own’ silver stocks:

    Watch the interview above for more of Durrett’s thoughts on those topics and more. You can also click here to view our Vancouver Resource Investment Conference playlist on YouTube.

    Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

    This post appeared first on investingnews.com

    previous post
    Chris Taylor Sets Sights on Gold, Antimony in France After Success at Great Bear
    next post
    Rio Tinto, Eurodia Team Up for Argentina Lithium Extraction

    Related Posts

    Rio Tinto Partners with Codelco to Develop Lithium...

    May 23, 2025

    How to Invest in Palladium Stocks, ETFs and...

    November 5, 2025

    US$200 Silver? 3 Experts Talk Price, Supply and...

    May 20, 2025

    ICMM: These 3 Nations Control Nearly Half the...

    September 4, 2025

    Gold vs. Platinum: Which is the True Metal...

    February 14, 2025

    Bidder’s Statement

    February 3, 2025

    Appendix 4D and Half Yearly Accounts

    February 27, 2025

    Convertible Note and Placement

    October 17, 2025

    Ericsson, Rogers Launch Canada’s First Underground 5G Network...

    June 21, 2025

    Blackrock Silver Announces Final Assays from Eastern Expansion...

    December 2, 2025

      Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


      By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

      Editors’ Picks

      • 1

        Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

        January 26, 2025
      • 2

        Financial Agreement signed releasing $2M grant

        January 23, 2025
      • 3

        Netflix shares soar as company reports surging revenue, tops 300 million subscribers

        January 23, 2025
      • 4

        Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

        January 23, 2025
      • 5

        Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

        January 23, 2025
      • 6

        US security contractor will take charge of key checkpoint in Gaza as Israeli forces withdraw

        January 25, 2025
      • 7

        FDA officially authorizes Zyn nicotine pouches for sale following health review

        January 23, 2025
      • About us
      • Contacts
      • Privacy Policy
      • Terms and Conditions
      • Email Whitelisting

      Disclaimer: wallstreetwizardry.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

      Copyright © 2026 wallstreetwizardry.com | All Rights Reserved